Dr. Sundy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Gilead Sciences
303 Velocity Way
Foster City, CA 94404Phone+1 650-577-6423- Is this information wrong?
Education & Training
- Duke University HospitalFellowship, Allergy and Immunology, 1995 - 1996
- Duke University HospitalFellowship, Rheumatology, 1994 - 1995
- Duke University HospitalResidency, Internal Medicine, 1991 - 1994
- Drexel University College of MedicineClass of 1991, MD, PhD
Certifications & Licensure
- NC State Medical License 1994 - 2024
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
- Join now to see all
Clinical Trials
- Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout Start of enrollment: 2004 Dec 01
- Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II Start of enrollment: 2003 Apr 01
- Genetics of Asthma - Bronchoscopy Studies Start of enrollment: 2007 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 25 citationsSafety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.Arthur Kavanaugh, Rene Westhovens, Kevin L. Winthrop, Susan J. Lee, Y. Tan, Di An, Lei Ye, John S. Sundy, R. Besuyen, L. Meuleners, Mykola Stanislavchuk, Alberto Spind...> ;The Journal of Rheumatology. 2021 Feb 1
- 98 citationsFilgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J. Abraham Simon, Herbert S B Baraf, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Gu...> ;Annals of the Rheumatic Diseases. 2021 Jan 27
- 2 citationsEfficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2)Tsutomu Takeuchi, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Mark C. Genovese, Kenneth C. Kalunian, David H. Wal...> ;Modern Rheumatology. 2021 Jan 18
- Join now to see all
Press Mentions
- The Drug Company That Prospered Without Creating Any DrugsApril 13th, 2023
- Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease TrialJanuary 4th, 2021
- Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 Was Well-Tolerated and Selectively Expanded Regulatory T CellsJanuary 4th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Alliance for Continuing Education in the Health ProfessionsMember
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: